NCT01484587View on ClinicalTrials.gov

A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 22, 2011

Primary Completion Date

April 11, 2013

Study Completion Date

April 11, 2013

Conditions
Psoriasis
Interventions
DRUG

CNTO 1959

CNTO 1959: type=range, unit=mg, number=10, 30, 100, 300, form=solution for injection, route=subcutaneous use, ascending dosing for 24 weeks

DRUG

Placebo

Placebo: form=solution for injection, route=subcutaneous use, ascending dosing for 24 weeks

Trial Locations (1)

Unknown

Sapporo

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY

NCT01484587 - A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter